Aug 29, 2019, 01:00 by admin admin

ASAM joined the Partnership to Amend 42 CFR Part 2 in expressing appreciation for SAMHSA's issuance of a notice of proposed rulemaking to modify 42 CFR Part 2, the regulations that govern confidentiality of drug and alcohol treatment and prevention records.

Aug 9, 2019, 01:00 by admin admin

When a patient seeks mental health care or treatment for a substance use disorder, the law makes clear that health insurers and regulators have legal obligations to ensure patients’ access to non-discriminatory care. We are very pleased that the Parity@10 Compliance Campaign will be taking an in-depth look at the significant challenges and barriers to care patients face when seeking treatment.

Aug 9, 2019, 01:00 by admin admin

In the wake of the introduction of the Overdose Prevention and Patient Safety (OPPS) Act, a bill that would amend the federal statute underlying the addiction treatment privacy regulations known as 42 CFR Part 2 (“Part 2”), ASAM has received many questions about our support for the bill and our position on changing Part 2.

Aug 9, 2019, 01:00 by admin admin

Today, the Department of Health and Human Services (HHS) issued their Mental Health and Substance Use Disorder Parity Action Plan. Congress included a provision in Section 13002 of the 21st Century Cutes Act requiring HHS to create this Action Plan detailing recent and planned actions from the Departments of HHS, Labor, and Treasury related to ongoing implementation of the Paul Wellstone and Pete Domenici Mental Health Parity and Addiction Equity Act (MHPAEA).

Aug 9, 2019, 01:00 by admin admin

The opioid epidemic continued throughout the United States in 2017. State legislatures have remained engaged on this issue, with every state enacting some type of measure supporting prevention, treatment, or recovery in the past two years.

Aug 9, 2019, 01:00 by admin admin

ASAM, working with the Partnership to Amend 42 CFR PArt 2, sent a letter urging lawmakers to align 42 CFR Part 2 with the Health Insurance Portability and Accountability Act (HIPAA)

Aug 9, 2019, 01:00 by admin admin

The Coalition to Stop Opioid Overdose (CSOO) enthusiastically welcomes Shatterproof as a new member of the Coalition. Shatterproof is a national nonprofit organization dedicated to ending the devastation addiction causes families.

Aug 9, 2019, 01:00 by admin admin

ASAM responded to an RFI regarding challenges, failures, fraud and abuse within the SUD treatment industry, as well as opportunities to improve the quality of treatment.

Aug 9, 2019, 01:00 by admin admin

Aug 9, 2019, 01:00 by admin admin

Dr. Mejzak stressed the importance of strengthening federal parity law enforcement at a roundtable discussion.

Aug 9, 2019, 01:00 by admin admin

On July 3, the American Society of Addiction Medicine (ASAM), American Academy of PAs (AAPA), American Association of Nurse Practitioners (AANP), and American Osteopathic Academy of Addiction Medicine (AOAAM), approved providers of DATA 2000 training, issued a letter to Attorney General Jeff Sessions thanking the Department of Justice (DOJ) for identifying individuals who may be committing opioid-related criminal activity and health care fraud involving patients with addiction and expressing the need to work together so such actions do not have unintended consequences that dissuade clinicians from prescribing buprenorphine and leave patients without treatment should their practitioners’ offices be closed.

Aug 9, 2019, 01:00 by admin admin

ASAM praised the House Appropriations Committee for including full funding for two new critical substance use disorder (SUD) workforce programs in its FY 2020 Labor, Health and Human Services (HHS), Education, and Related Agencies appropriations bill.

Aug 9, 2019, 01:00 by admin admin

Today, the American Society of Addiction Medicine (ASAM) submitted comments to the Centers for Medicare & Medicaid Services (CMS) that recommend revisions to the proposed 2019 Medicare Physician Fee Schedule (MPFS) that will improve the delivery of evidence-based addiction medicine to combat the nation’s opioid overdose epidemic.

Aug 9, 2019, 01:00 by admin admin

On Friday, June 16th, President Trump’s Commission on Combatting Drug Addiction and the Opioid Crisis held a teleconference to discuss the Opioid Commission’s work and included participants from nine national non-profit organizations as well senior members of the Trump administration.

Aug 9, 2019, 01:00 by admin admin

CSOO and MHLG hosted a roundtable discussion with Congressman David Trone to discuss legislative efforts in Congress regarding mental health and addiction.

Aug 9, 2019, 01:00 by admin admin

ASAM offered detailed recommendations for addressing the opioid epidemic.

Aug 9, 2019, 01:00 by admin admin

The Journal of Law, Medicine & Ethics has accepted a letter to the editor urging the Accreditation Council for Graduate Medical Education (ACGME) establish a requirement that all residents and fellows who care for patients who use opioids, as well as their core faculty, receive specific training on the treatment of opioid use disorder (OUD).

Aug 9, 2019, 01:00 by admin admin

Today the American Society of Addiction Medicine (ASAM) submitted a letter to the House Committee on Energy and Commerce as it considers legislation to address the opioid misuse, addiction, and overdose epidemic. The letter, submitted to Chairman Greg Walden (R-OR) and Ranking Member Frank Pallone (D-NJ), urges the Committee to approve bills that expand the provision of evidence-based treatment, strengthen America’s addiction treatment infrastructure, and bolster the nation’s addiction treatment workforce.

Aug 9, 2019, 01:00 by admin admin

Updated definition of addiction to explain more fully the complexity of this chronic disease with the intent of driving a bold and comprehensive national response.

Aug 9, 2019, 01:00 by admin admin

On May 16, the Food and Drug Administration (FDA) announced its approval Lucemyra, the first non-opioid treatment for management of opioid withdrawal symptoms. Lucemyra (lofexidine hydrochloride) reduces the release of norepinephrine and can be used to lessen the severity of withdrawal symptoms that may occur after the discontinuation of opioid use.